Crispr Therapeutics is trading at $52.22, up 4.46%, with broader biotech strength appearing to be the likeliest driver.
- XBI is up 2.13%, alongside gains in major U.S. indices.
- No company-specific announcement clearly explains the morning rise. The November 2 earnings update showed $99 million in CASGEVY program revenue, but also a quarterly net loss.
- Wells Fargo subsequently cut its price target; those developments do not clearly account for today’s gain.